Hepatitis A IgM Test

If you have sudden fatigue, dark urine, nausea, or yellowing skin and eyes, blood tests will show your liver enzymes are elevated. But elevated enzymes only tell you the liver is inflamed. They cannot tell you why. Hepatitis A, B, C, and E all look identical on a standard liver panel, and so do drug reactions, autoimmune flares, and alcohol-related damage. Without a specific antibody test, the cause stays hidden.

Anti-HAV IgM (immunoglobulin M antibody against hepatitis A virus) fills that gap. It is the first antibody your body makes when hepatitis A virus enters your system, and it shows up in your blood before most people even feel sick. A positive result confirms active or very recent hepatitis A, while a negative result effectively rules it out and redirects the search elsewhere.

What This Antibody Tells You

IgM is the class of antibody your immune system deploys first during any new infection. Think of it as a rapid-response team: large, powerful, and temporary. Your body's B cells begin producing anti-HAV IgM within about two weeks of exposure to hepatitis A virus, which means antibody levels start rising roughly 5 to 10 days before symptoms appear. They peak within the first month of illness and then gradually fade.

In most people, anti-HAV IgM drops to undetectable levels within six months. After that, a different antibody, IgG (immunoglobulin G), takes over and provides lifelong protection against reinfection. The IgM test specifically targets that early window, making it the right test when you need to know whether a hepatitis A infection is happening right now, not whether one happened in the past.

Acute Hepatitis A: What to Expect

Hepatitis A is a liver infection spread through contaminated food, water, or close contact with an infected person. When the virus reaches the liver, it triggers an intense inflammatory response. Liver enzymes called ALT and AST surge, often rising dramatically. In confirmed acute cases, average peak ALT values have been measured around 1,920 IU/L. Bilirubin, the pigment that causes jaundice, also climbs. About 90% of confirmed acute cases develop visible jaundice.

The good news is that hepatitis A does not become chronic. Unlike hepatitis B or C, it does not linger in the liver for years causing slow damage. Bilirubin and liver enzyme levels typically return to normal within two to three months. The vast majority of people recover fully with only supportive care: rest, fluids, and time.

The rare but serious exception is fulminant hepatitis, where the liver fails rapidly. In a study of 29 people who developed hepatitis A-related acute liver failure, a kidney function marker (creatinine) above 2 mg/dL, low ALT (below 2,600 IU/L), the need for a breathing tube, and the need for blood pressure medications were predictors of death or the need for transplant. Transplant-free survival in this group was only 55%. This is uncommon, but it shows why confirming the cause of acute hepatitis matters: it shapes how aggressively you and your medical team monitor the recovery.

How the Test Is Interpreted

Anti-HAV IgM is reported as a qualitative result: positive (reactive) or negative (non-reactive). There are no numeric ranges to interpret in the way you would read a cholesterol number. Different lab platforms use slightly different internal scoring systems, but the result you receive is simply positive or negative.

A positive result in someone with symptoms of acute hepatitis, such as jaundice, elevated liver enzymes, fever, and dark urine, confirms the diagnosis. A negative result in the same setting effectively rules out hepatitis A and points the investigation toward other causes.

When Results Can Be Misleading

The biggest source of error with this test is false-positive results, and they happen most often when the test is ordered in people who are unlikely to actually have hepatitis A. In populations where fewer than 5% of people tested have the disease, the chances of a positive result being wrong rise substantially. One study found that when the test was ordered routinely for patients with chronic liver disease in outpatient settings, only 4 out of 35 positive results turned out to be true acute hepatitis A.

Low-level positive results are especially unreliable. Research using the Abbott Architect testing platform found that all confirmed acute cases had antibody values above 4.0 (on that platform's internal scale, with a mean of 9.4), while 63.6% of patients with low-level positive results turned out to have a completely different diagnosis. If you receive a weakly positive result without classic symptoms, confirmatory testing with a molecular test (called a nucleic acid amplification test, or NAAT) that looks for the virus's genetic material directly can settle the question.

A few other situations can produce misleading results. If you received a hepatitis A vaccine within the past two to three weeks, 8 to 20% of adults will test positive for IgM antibodies during that window, even though they are not infected. Infections with other viruses, particularly Epstein-Barr virus (the virus behind mono), cytomegalovirus, and hepatitis E, can sometimes trigger cross-reactive antibodies that produce a false positive. High-dose biotin supplements (at concentrations of 1,200 ng/mL in laboratory testing) can interfere with certain test platforms. On the VITROS platform studied, biotin caused false-negative IgM results at a rate of 6.7%. Other streptavidin-biotin-based platforms may be similarly affected. If you take biotin at high doses, mention this to your provider before testing.

Sex Differences in Antibody Response

Women tend to produce a stronger and longer-lasting IgM response to hepatitis A than men. In a study of 102 cases across two outbreaks, women had significantly higher antibody levels and a higher likelihood of remaining IgM-positive over time. At five months after symptom onset, 38% of women were still testing positive for anti-HAV IgM, compared to 0% of men. This means a positive result in a woman months after initial illness is more likely to reflect a lingering immune response rather than a new or ongoing infection.

Tracking Over Time

Because anti-HAV IgM is a diagnostic test for a single event (an acute infection), it does not lend itself to the kind of serial tracking you would use for cholesterol or blood sugar. You are not measuring a continuous biological variable; you are answering a yes-or-no question: is there an active infection right now?

That said, a repeat test does have value in specific situations. If your initial result was a weak positive without clear symptoms, retesting in two to four weeks can clarify whether antibody levels are rising (suggesting true infection) or stable and low (suggesting a false positive). If you tested positive during confirmed acute hepatitis A and symptoms have resolved, a follow-up test after six months can confirm that IgM has cleared and that your immune system has transitioned to the protective IgG phase.

For ongoing immunity monitoring after recovery or vaccination, the appropriate test is total anti-HAV or anti-HAV IgG, not IgM. The IgM test is built for the acute window, not for long-term surveillance.